cariboubio.comHealthcareFounded: 2011Funding to Date: $41.55MM
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.
View Enterprise Value for Caribou Biosciences.